Evidence map›Paper›PMID 39674361›Full record

ReviewExperimental hematology2025

Understanding Human Oncogene Function and Cooperativity in Myeloid Malignancy Using iPSCs.

Martina Sarchi, Sergei Doulatov

Abstract readReview
In one paragraph

Review in Experimental hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Martina SarchiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Sergei DoulatovDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA; Department of Genome Sciences, University of Washington, Seattle, WA; Institute of Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA. Electronic address: doulatov@uw.edu.

Funding

Development of Innovative Resources to Advance MDS ResearchRC2DK127989 · NIDDK · FRED HUTCHINSON CANCER CENTER · PI Marie Bleakley, Sergei Doulatov · 2023 to 2026
$6.2M
Functional and molecular consequences of SF3B1 mutations in human hematopoietic stem cellsR01HL151651 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Robert K Bradley, Sergei Doulatov · 2020 to 2026
$4.0M
Uncovering epigenetic barriers to hematopoietic stem cell formationDP2HL147126 · NHLBI · UNIVERSITY OF WASHINGTON · PI DOULATOV, SERGEI · 2018 to 2018
$2.3M
The role of lamin B1 in normal and myelodysplastic hematopoiesisR01HL169156 · NHLBI · UNIVERSITY OF WASHINGTON · PI Sergei Doulatov · 2023 to 2026
$2.1M
NHLBI NIH HHS DP2 HL147126NHLBI NIH HHS R01 HL151651NHLBI NIH HHS R01 HL169156NIDDK NIH HHS RC2 DK127989
6 · The paper itself

Abstract

Myeloid malignancies are a spectrum of clonal disorders driven by genetic alterations that cooperatively confer aberrant self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPCs). Induced pluripotent stem cells (iPSCs) can be differentiated into HSPCs and have been widely explored for modeling hematologic disorders and cell therapies. More recently, iPSC models have been applied to study the origins and pathophysiology of myeloid malignancies, motivated by the appreciation for the differences in human oncogene function and the need for genetically defined models that recapitulate leukemia development. In this review, we will provide a broad overview of the rationale, the challenges, practical aspects, history, and recent advances of iPSC models for modeling myeloid neoplasms. We will focus on the insights into the previously unknown aspects of human oncogene function and cooperativity gained through the use of these models. It is now safe to say that iPSC models are a mainstay of leukemia modeling "toolbox" alongside primary human cells from normal and patient sources.

Indexed as

Induced Pluripotent Stem CellsLeukemia, MyeloidMyeloproliferative DisordersOncogenesAnimalsCell DifferentiationHematopoietic Stem CellsHumans

Identifiers

PMID39674361
PMCPMC12463382

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.